What Abiomed does

Abiomed, founded in 1981 and headquartered in Danvers, Massachusetts, develops, manufactures, and markets mechanical circulatory support devices, with the Impella family of percutaneous ventricular assist devices (pVADs) as its core franchise. The Impella platform — including Impella CP, Impella 5.5, Impella RP, and Impella RP Flex — provides temporary ventricular unloading and circulatory support to patients in cardiogenic shock, high-risk PCI, and post-cardiotomy settings, complemented by the SmartAssist sensor/algorithm platform, Companion Sheath, and the Impella Connect cloud-based remote monitoring system. More than 400,000 patients have been treated to date, supported by over 1,500 peer-reviewed clinical studies and inclusion in 17 clinical guidelines.

The company monetizes primarily through sale of single-use Impella catheters and associated consoles to hospitals and health systems, reaching interventional cardiologists, cardiac surgeons, and advanced heart-failure teams via an enterprise field-sales force; revenue is generated per procedure, with console placement and software subscriptions creating a recurring infrastructure layer. The portfolio has been broadened through acquisitions including Impella Cardiosystems (2005), ECP Entwicklungsgesellschaft (2014), Breethe (2020, ECMO), and preCARDIA (2021, acute decompensated heart failure), and a January 2026 partnership with Lexeo Therapeutics explores Impella-enabled delivery of cardiac gene therapies.

Abiomed was acquired by Johnson & Johnson MedTech for $16.6 billion in November 2022 and now operates as a wholly owned subsidiary, no longer trading publicly on NASDAQ. Reported FY2025 Impella revenue was $1.751 billion, with 18% operational growth in Q4 FY2025; the franchise has faced defensive regulatory events including an FDA Class I recall on Impella heart pumps and an FDA early alert on catheter introducer kits manufactured with Oscor, alongside a patent trial victory against Maquet Cardiovascular in May 2026.

Name

Abiomed

Legal name

ABIOMED

Website

https://abiomed.com

Company type

Private

Founded year

1981

Operating status

Acquired

Headcount range

1,001–5,000 employees

Short description

Abiomed, a Johnson & Johnson MedTech subsidiary, develops and markets the Impella percutaneous ventricular assist device platform, providing temporary mechanical circulatory support to cardiogenic shock, high-risk PCI, and advanced heart-failure patients in hospital cath labs and surgical settings.

Ownership category

akta.pro rank

Product category

Cardiovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industries

Interventional Cardiology (PCI/Structural Heart) (HLAKABAB), Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Heart Failure & Transplant Cardiology (HLAKABAD)

Keywords

• Percutaneous ventricular assist devices
• Mechanical circulatory support
• Microaxial heart pumps
• Cardiogenic shock treatment
• Protected PCI devices

Headquarters

HQ city

Danvers

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Impella Heart Pump Sales: Abiomed generates revenue through the sale of Impella heart pump devices and related accessories including catheters, controllers, and support equipment to hospitals and healthcare providers. The company also derives revenue from service agreements and clinical support programs. Impella series generated $1.751 billion in worldwide revenue in fiscal year 2025.
2. Impella Connect Services: Remote monitoring and connected care services for Impella devices through the Impella Connect platform, enabling hospitals to monitor device performance and patient status remotely.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Abiomed develops, manufactures, and sells the Impella family of catheter-based microaxial flow heart pumps that provide temporary mechanical circulatory support for patients in cardiogenic shock, undergoing high-risk percutaneous coronary interventions, or experiencing right heart failure. The portfolio also includes the preCARDIA catheter system for acute decompensated heart failure and the Impella Connect remote monitoring platform, sold to hospitals and healthcare systems globally.

Product overview

Abiomed offers the Impella family of percutaneous ventricular assist devices (pVADs), a comprehensive portfolio of temporary mechanical circulatory support systems. The core product line includes Impella 5.5, Impella CP, Impella RP, and Impella RP Flex heart pumps, all designed to provide hemodynamic support during high-risk procedures or cardiogenic shock. The portfolio includes companion technologies such as SmartAssist sensor technology for enhanced monitoring, the Companion Sheath for improved device insertion, and Impella Connect for remote monitoring. In 2021, Abiomed expanded its portfolio by acquiring preCARDIA, adding a proprietary catheter and controller system for treating acute decompensated heart failure.

Differentiator

Problem solved

Functional benefit

Brands

• Impella: The Impella heart pump product line, including Impella CP, Impella 5.5, Impella RP, and Impella RP Flex. These are percutaneous ventricular assist devices (pVAD) used for treating high-risk PCI, cardiogenic shock, and heart failure.
• Impella Connect
• ABIOMED Collaborative Care
• SmartAssist
• HeartRecovery

Products and services

• Impella CP with SmartAssist A catheter-based micro-axial heart pump offering temporary left ventricular support for up to 6 hours, designed for protected PCI and cardiogenic shock patients in hospital cath lab settings.
• Impella 5.5 with SmartAssist A percutaneous ventricular assist device (pVAD) providing higher-output temporary mechanical circulatory support for patients with cardiogenic shock or undergoing high-risk PCI procedures.
• Impella RP with SmartAssist A percutaneous right ventricular assist device providing temporary support for right heart failure patients.
• Impella RP Flex with SmartAssist A next-generation right ventricular assist device with enhanced flexibility for improved insertion and positioning.
• Companion Sheath A specialized introducer sheath designed to facilitate insertion and removal of Impella heart pumps during procedures.
• SmartAssist Technology An advanced sensor and algorithmic technology integrated into Impella devices providing real-time hemodynamic monitoring and positioning assistance during procedures.
• Impella Connect A cloud-based remote monitoring platform enabling healthcare providers to monitor Impella device performance and patient data in real-time.
• preCARDIA system A catheter-based system designed to treat acute decompensated heart failure (ADHF) by reducing cardiac filling pressures and promoting decongestion.
• ABIOMED Collaborative Care A service program providing clinical support, training, and ongoing practice assistance for hospitals and healthcare providers using Impella heart pumps, including 24-hour clinical support.

Quantifiable outcome

• Over 400,000 patients have been treated with Impella heart pumps
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Lexeo TherapeuticscoreStrategic or Co-development Partner · 8 January 2026Lexeo Therapeutics partnered with Abiomed to use Impella heart pump technology as a novel preclinical method for delivering cardiac gene therapy directly to the heart. The approach aims to concentrate AAV delivery locally to reduce required doses, minimize immune responses, and improve safety compared to conventional systemic delivery methods.
• preCARDIAcoreStrategic or Co-development Partner · 1 June 2021Abiomed acquired preCARDIA, a medical device company specializing in treatments for acute decompensated heart failure. The preCARDIA system includes a proprietary catheter and controller designed to treat ADHF by reducing cardiac filling pressures and promoting decongestion, with promising clinical results and regulatory progress including FDA Breakthrough Device Designation.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• LivaNova: Cardiac surgery and cardiopulmonary company that acquired the TandemHeart pVAD platform. Directly competes in temporary mechanical circulatory support for cardiogenic shock and high-risk PCI.
• Getinge (Maquet Cardiovascular): Direct competitor via its Maquet Cardiovascular subsidiary, which produces intra-aortic balloon pumps, ECMO/cardiopulmonary support systems, and centrifugal pumps. Was the plaintiff in the recent patent dispute with Abiomed over intravascular heart pump technology.

Regional players

• Fresenius Medical Care (Xenios): Owns Xenios, a European-based ECMO and cardiopulmonary support specialist. Competes with Impella in cardiogenic shock via extracorporeal life support, particularly in European markets.

Broad incumbents

• Edwards Lifesciences: Structural heart and critical care leader with the Swan-Ganz catheter line and critical care monitoring. Competes in the interventional cardiology and hemodynamic monitoring space adjacent to Impella's use cases.
• Medtronic: Global medical device leader with cardiac surgery, structural heart, and heart failure offerings including extracorporeal support. Overlaps with Abiomed's cath-lab and surgical circulatory support categories as part of a much broader portfolio.
• Terumo (Terumo Cardiovascular): Cardiovascular and cardiac surgery systems provider offering oxygenators, perfusion circuits, and interventional products. Competes with Abiomed in surgical applications and shares cath-lab customer relationships.
• Abbott: Large cardiovascular device incumbent offering HeartMate 3 LVAD, centriMag acute circulatory support, and a broad structural heart portfolio. Directly competes with Abiomed across multiple mechanical circulatory support and heart failure segments.

Emerging players

• Berlin Heart: Specialist in ventricular assist devices, notably the EXCOR pediatric VAD. Adjacent niche competitor in mechanical circulatory support focused on pediatric and long-duration applications distinct from Abiomed's percutaneous adult focus.
• Cardiobridge (part of Terumo): Developer of the Reitan catheter-based pump for temporary mechanical circulatory support. Direct emerging competitor to Impella in the percutaneous pVAD category used during high-risk PCI and cardiogenic shock.

Others

• Shockwave Medical: Sister J&J MedTech company specializing in intravascular lithotripsy for calcified lesions. Highly relevant strategic peer as a fellow cardiovascular franchise within the same J&J portfolio addressing cath-lab physicians.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/abiomedimpella
• Facebookfacebook.com/abiomed
• LinkedInlinkedin.com/company/abiomed

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abiomed